Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Fineline Cube Jan 29, 2026
Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026
Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026
Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026
Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026
Company Deals Drug

BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009

Fineline Cube Mar 28, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotechnology company, has entered into...

Company

RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments

Fineline Cube Mar 28, 2024

RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023...

Company Drug

Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP

Fineline Cube Mar 28, 2024

Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour...

Company

Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts

Fineline Cube Mar 28, 2024

Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...

Company

AstraZeneca’s Soriot Discusses US BioSecure Act’s Impact Amid China Expansion Plans

Fineline Cube Mar 28, 2024

Pascal Soriot, CEO of AstraZeneca (NASDAQ: AZN), addressed the potential implications of the US BioSecure...

Company Deals

Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals

Fineline Cube Mar 28, 2024

Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...

Company Drug

HutchMed’s Orpathys Files for Expanded Indication in NSCLC Treatment in China

Fineline Cube Mar 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma

Fineline Cube Mar 28, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center...

Policy / Regulatory

China Unveils Management Measures to Strengthen National Health Emergency Teams

Fineline Cube Mar 28, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Hospital Policy / Regulatory

China’s NHC Mandates Enhanced Management and Accessibility of Midwifery Services

Fineline Cube Mar 28, 2024

The National Health Commission (NHC) has issued a notification with the aim of enhancing the...

Company Medical Device

AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software

Fineline Cube Mar 28, 2024

AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic...

Company Deals

BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies

Fineline Cube Mar 28, 2024

A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has...

Company

Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance

Fineline Cube Mar 28, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...

Company

MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials

Fineline Cube Mar 28, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...

Company

Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales

Fineline Cube Mar 28, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...

Company

CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand

Fineline Cube Mar 28, 2024

CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...

Company Deals

Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies

Fineline Cube Mar 28, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...

Medical Device R&D

Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices

Fineline Cube Mar 28, 2024

Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...

Company Drug

Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases

Fineline Cube Mar 28, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...

Company Deals

Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai

Fineline Cube Mar 27, 2024

Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...

Posts pagination

1 … 332 333 334 … 616

Recent updates

  • Organon Completes $465M JADA System Sale to Laborie Medical
  • MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study
  • Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
  • Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
  • Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.